Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Intellia Therapeutics, Inc. - Common Stock
(NQ:
NTLA
)
10.97
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intellia Therapeutics, Inc. - Common Stock
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
21
22
Next >
Expert Ratings for Intellia Therapeutics
↗
January 24, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
↗
January 24, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
January 20, 2023
Friday saw 23 companies set new 52-week lows.
Via
Benzinga
The Latest Analyst Ratings for Intellia Therapeutics
↗
January 04, 2023
Via
Benzinga
Analyst Ratings for Intellia Therapeutics
↗
December 02, 2022
Via
Benzinga
Intellia's Hereditary Angioedema Candidate Shows Reduction In Associated Biomarkers, Attack Rates
↗
November 14, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
↗
January 19, 2023
Via
Benzinga
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
↗
January 07, 2023
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.
Via
The Motley Fool
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
↗
December 30, 2022
Both stocks have fallen brutally this year, but only one has a chance to recover soon.
Via
The Motley Fool
Recap: Intellia Therapeutics Q3 Earnings
↗
November 03, 2022
Intellia Therapeutics (NASDAQ:NTLA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
7 Analysts Have This to Say About Intellia Therapeutics
↗
October 11, 2022
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:
Via
Benzinga
3 Mid-Caps That Could Double in 2023
December 15, 2022
Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months.
Via
MarketBeat
7 ‘Next Big Things’ for Investors to Buy for 2023
↗
December 13, 2022
The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.
Via
InvestorPlace
Ulta Beauty To Rally Around 22%? Here Are 10 Other Price Target Changes For Friday
↗
December 02, 2022
Via
Benzinga
NTLA Stock Falls as Intellia Therapeutics Announces Public Offering
↗
December 01, 2022
Intellia Therapeutics (NTLA) stock is falling hard on Thursday after the company announced a public stock offering of 6.6 million shares.
Via
InvestorPlace
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing
↗
November 28, 2022
Here's how Ark Invest's top holdings have performed in 2022.
Via
Investor's Business Daily
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
↗
November 15, 2022
Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.
Via
Benzinga
Earnings Preview For Intellia Therapeutics
↗
November 02, 2022
Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
↗
November 01, 2022
Upgrades
Via
Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
↗
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
3 Cathie Wood Stocks to Buy and Hold for 10 Years
↗
October 19, 2022
The risks are formidable, but the chances of a massive gain are too much to pass up.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
↗
October 11, 2022
Upgrades
Via
Benzinga
The Top 5 Stocks Cathie Wood Is Buying This Week
↗
September 23, 2022
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
↗
September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago...
Via
Benzinga
5 Top Stocks Cathie Wood Is Buying Right Now
↗
September 19, 2022
Cathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies.
Via
InvestorPlace
SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To Know
↗
September 19, 2022
SVB Leerink has decided to maintain its Outperform rating of Intellia Therapeutics (NASDAQ:NTLA) and raise its price target from $152.00 to $158.00. Shares of Intellia Therapeutics are trading down...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Intellia Therapeutics
↗
September 19, 2022
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings:
Via
Benzinga
This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedEx
↗
September 19, 2022
Wells Fargo lowered the price target for Adobe Inc. (NASDAQ: ADBE) from $425 to $310. Adobe shares fell 1.2% to $296.04 in pre-market trading.
Via
Benzinga
Why Is Applied Optoelectronics (AAOI) Stock Up 35% Today?
↗
September 16, 2022
Applied Optoelectronics (AAOI) stock is climbing higher on Friday after the company revealed a $150 million asset sale and new brand launch.
Via
InvestorPlace
Why Is Esports Entertainment (GMBL) Stock Down 45% Today?
↗
September 16, 2022
Esports Entertainment (GMBL) stock is falling hard on Friday after the company revealed the pricing of a public stock offering.
Via
InvestorPlace
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
